Literature DB >> 6190915

Idiotypic and fluorometric analysis of the antibodies that distinguish the lesion of the I-A mutant B6.C-H-2bm12.

M R Melino, S L Epstein, D H Sachs, T H Hansen.   

Abstract

The serologic lesion of the I-A mutant mouse strain, bm12, was investigated with the use of monoclonal anti-Iab antibodies and anti-idiotypic (Id) reagents produced against these antibodies. In a fluorometric analysis, three different monoclonal anti-Iab antibodies (25-9-17, 34-5-3, 28-16-8) failed to bind bm12 cells, whereas two anti-Iab antibodies (25-5-16 and 17/227), which bound bm12 cells, showed about one-half the fluorescence intensity that they showed in binding to Iab antigens. Of the three monoclonal antibodies that failed to react with bm12 cells, two antibodies (25-9-17 and 34-5-3) were found to bind the same steric site on Iab molecules (cluster I). In contrast, the antibodies (25-5-16 and 17/227) that reacted with both Iab and Iabm12 antigens were found to bind a second distinct site (cluster II). The binding of antibody 28-16-8 to Iab antigens inhibited reciprocally the binding of cluster I and II anti-Iab antibodies, suggesting a possible third site, sterically located intermediate between the other two sites. To assess the relatedness of the antibodies defining the serologic lesion of bm12 mice, xenogeneic and syngeneic anti-Id reagents were produced against antibodies 25-9-17 and 28-16-8. By using these anti-Ids in a binding site-related inhibition assay, a cross-reactive idiotype was detected that is shared by 25-9-17 and 34-5-3 antibodies; thus these two monoclonal antibodies share several features, including 1) idiotypic determinants, 2) failure to bind bm12 cells, 3) binding the same spatial Iab site, and 4) having indistinguishable serologic fine specificity that corresponds with a previously defined predominant alloantigenic determinant recognized in the bm12 anti-Iab humoral response. Therefore, several parameters of antibody recognition of Ia can now be correlated with structural changes in Ia molecules. These findings will potentiate future studies of the T cell recognition of these same Ia epitopes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190915

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  In vivo inhibition of anti-Thy-1 response by monoclonal antibody to the A molecules of the responder.

Authors:  M B Zaleski; T J Gorzynski; L J Quackenbush; W K Dowjat
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

2.  Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities.

Authors:  F Perosa; S Ferrone
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

3.  A previously unappreciated polymorphism in the beta chain of I-As expressed in autoimmunity-prone SJL mice: Combined impact on antibody, CD4 T cell recognition and MHC class II dimer structural stability.

Authors:  Katherine A Richards; Courtney Lavery; Grant L J Keller; Jim Miller; Brian M Baker; Andrea J Sant
Journal:  Mol Immunol       Date:  2022-01-05       Impact factor: 4.174

4.  Novel CD8 T cell alloreactivities in CCR5-deficient recipients of class II MHC disparate kidney grafts.

Authors:  Daisuke Ishii; Joshua M Rosenblum; Taiji Nozaki; Austin D Schenk; Kiyoshi Setoguchi; Charles A Su; Victoria Gorbacheva; William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

5.  Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations.

Authors:  W M Kast; A M Bronkhorst; L P de Waal; C J Melief
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

6.  The QTL within the H2 Complex Involved in the Control of Tuberculosis Infection in Mice Is the Classical Class II H2-Ab1 Gene.

Authors:  Nadezhda Logunova; Maria Korotetskaya; Vladimir Polshakov; Alexander Apt
Journal:  PLoS Genet       Date:  2015-11-30       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.